At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture

Kyung S.oo Suk, Hwan M.o. Lee, Seong Hwan Moon, Hee J.une Kim, Hak S.un Kim, Jin Oh Park, Byung H.o. Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M).

MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272).

RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006).

CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy.

Original languageEnglish
Pages (from-to)1576-1583
Number of pages8
JournalYonsei medical journal
Volume55
Issue number6
DOIs
Publication statusPublished - 2014 Nov 1

Fingerprint

Teriparatide
Compression Fractures
Insurance
Osteoporosis
Odds Ratio
Therapeutic Uses
Survival Analysis
Osteogenesis
Bone Density
Body Mass Index
Cohort Studies
Therapeutics
Survival Rate
Retrospective Studies
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Suk, Kyung S.oo ; Lee, Hwan M.o. ; Moon, Seong Hwan ; Kim, Hee J.une ; Kim, Hak S.un ; Park, Jin Oh ; Lee, Byung H.o. / At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture. In: Yonsei medical journal. 2014 ; Vol. 55, No. 6. pp. 1576-1583.
@article{b005faddd75e4a8da315c3a043dcc251,
title = "At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture",
abstract = "PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M).MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272).RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006).CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy.",
author = "Suk, {Kyung S.oo} and Lee, {Hwan M.o.} and Moon, {Seong Hwan} and Kim, {Hee J.une} and Kim, {Hak S.un} and Park, {Jin Oh} and Lee, {Byung H.o.}",
year = "2014",
month = "11",
day = "1",
doi = "10.3349/ymj.2014.55.6.1576",
language = "English",
volume = "55",
pages = "1576--1583",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture. / Suk, Kyung S.oo; Lee, Hwan M.o.; Moon, Seong Hwan; Kim, Hee J.une; Kim, Hak S.un; Park, Jin Oh; Lee, Byung H.o.

In: Yonsei medical journal, Vol. 55, No. 6, 01.11.2014, p. 1576-1583.

Research output: Contribution to journalArticle

TY - JOUR

T1 - At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture

AU - Suk, Kyung S.oo

AU - Lee, Hwan M.o.

AU - Moon, Seong Hwan

AU - Kim, Hee J.une

AU - Kim, Hak S.un

AU - Park, Jin Oh

AU - Lee, Byung H.o.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M).MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272).RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006).CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy.

AB - PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M).MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272).RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006).CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy.

UR - http://www.scopus.com/inward/record.url?scp=84930895664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930895664&partnerID=8YFLogxK

U2 - 10.3349/ymj.2014.55.6.1576

DO - 10.3349/ymj.2014.55.6.1576

M3 - Article

C2 - 25323894

AN - SCOPUS:84930895664

VL - 55

SP - 1576

EP - 1583

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -